Nilotinib
Who holds supplier records for Nilotinib? 7 organisations hold a current record for Nilotinib: an active US FDA Type II Drug Master File. A further 2 organisations have only historical (inactive) DMF filings. Recorded organisation countries for current records: India (4), Netherlands (1) and Israel (1); not recorded for 1.
Most records are filed under another form of this substance: Nilotinib Hydrochloride Monohydrate (8 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Nilotinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/nilotinib
Reading the evidence
- 7 current records
Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.
- Most recorded organisations are in India
4 of the 6 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.
- 4 with a company-level GMP certificate on record
These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Nilotinib expires 30 Apr 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (7)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Nilotinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
- MSN Laboratories Private LimitedIndia Company GMP cert on recordActive DMF 35729, 32661, 41318 +1 · latest filing Mar 2025
- Dr. Reddy's Laboratories Ltd.India Company GMP cert on recordActive DMF 43272, 30088 · latest filing Dec 2025
- TAPI NL BVNetherlandsActive DMF 37242, 28102 · latest filing Sept 2022
- Hetero Labs LimitedIndia Company GMP cert on recordActive DMF 30098 · latest filing Dec 2015
- SHILPA PHARMA LIFESCIENCES LTDIndiaActive DMF 36289 · latest filing Sept 2021
- SICHUAN ELIXIR PHARMACEUTICAL CO LTDActive DMF 39648 · latest filing Mar 2024
- Teva Pharmaceutical Industries Ltd.Israel Company GMP cert on recordActive DMF 34874 · latest filing Jul 2020
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
Historical records (2)
Organisations whose Type II DMFs for Nilotinib are no longer active. These show a past filing, not current supply.
Show all 2 historical records
- Italy · Inactive DMF 31740 · filed Jun 2017
- Sichuan Xieli Pharmaceutical Co LtdChina · Inactive DMF 26497 · filed Sept 2012
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (23 listed products contain Nilotinib). The latest listed patent expires 30 Apr 2041. The latest listed exclusivity runs to 23 Mar 2029. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Nilotinib is a tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. It works by blocking the BCR-ABL kinase and improving patient outcomes in cases resistant to previous treatments.
Chemical identity
- IUPAC name
- 4-methyl-N-[3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide
- Canonical SMILES
- CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)C(F)(F)F)N3C=C(N=C3)C)NC4=NC=CC(=N4)C5=CN=CC=C5
- InChIKey
- HHZIURLSWUIHRB-UHFFFAOYSA-N
- Synonyms
- Tasigna API, amn-107, amn107, nsc-747599
Pharmacologic class
As the US FDA states it for this active substance on product listings.
- Established pharmacologic class
- Kinase Inhibitor
- Mechanism of action
- Bcr-Abl Tyrosine Kinase Inhibitors; Cytochrome P450 2B6 Inducers; Cytochrome P450 2C8 Inducers; Cytochrome P450 2C8 Inhibitors; Cytochrome P450 2D6 Inhibitors; P-Glycoprotein Inhibitors; UGT1A1 Inhibitors
Therapeutic areas
Record history
No change to the current records between 13 Nov 2026 and 16 Nov 2026.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Which organisations hold current supplier records for Nilotinib?
7 organisations hold an active US FDA Type II Drug Master File or a CEP for Nilotinib: MSN Laboratories Private Limited (India), Dr. Reddy's Laboratories Ltd. (India), TAPI NL BV (Netherlands), Hetero Labs Limited (India), SHILPA PHARMA LIFESCIENCES LTD (India), SICHUAN ELIXIR PHARMACEUTICAL CO LTD and Teva Pharmaceutical Industries Ltd. (Israel). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.
Which Nilotinib Drug Master Files are active?
MSN Laboratories Private Limited (DMF 35729, 32661), Dr. Reddy's Laboratories Ltd. (DMF 43272, 30088), TAPI NL BV (DMF 37242, 28102), Hetero Labs Limited (DMF 30098), SHILPA PHARMA LIFESCIENCES LTD (DMF 36289), SICHUAN ELIXIR PHARMACEUTICAL CO LTD (DMF 39648) and Teva Pharmaceutical Industries Ltd. (DMF 34874). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.
What do the historical Nilotinib records mean?
2 organisations have only inactive Type II DMFs for Nilotinib. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.
Does the FDA Orange Book list patents for products containing Nilotinib?
Yes. The latest patent listed for an approved US product containing Nilotinib expires 30 Apr 2041, across 23 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Nilotinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Nilotinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.